Synlogic (SYBX) Reports Q3 Loss of $0.43, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Synlogic Reports Third Quarter 2018 Financial Results and Provides Program Updates
November 13, 2018 4:05 PM ESTAdvancement of SYNB1891, the first Synthetic Biotic immuno-oncology candidate to enable Investigational New Drug Application (IND) filing in 2H 2019
Ongoing clinical trials of SYNB1020 and SYNB1618 in patients with data expected in 2019
Management to host conference call and webcast at 5:00 pm ET today
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Synlogic, Inc. (Nasdaq: SYBX), a... More
